Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety
Φόρτωση...
Ημερομηνία
Συγγραφείς
Lazaridis, G.
Pentheroudakis, G.
Pavlidis, N.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Crit Rev Oncol Hematol
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
Neoadjuvant chemotherapy is used in non-metastatic breast cancer in order to eradicate micrometastatic deposits early during disease course, as well as in order to decrease tumour bulk and render surgery feasible or breast-conserving. Moreover, it offers promise to serve as an in vivo chemosensitivity assay and as a powerful predictive factor for outcome. Trastuzumab, a monoclonal antibody targeting an epitope in the extracellular domain of the Human Epidermal Growth Factor Receptor-2 (HER2/erbB-2), was found to be active in HER2-overexpressing metastatic as well as in resected breast cancer when given post-operatively. In this review, we summarise the evidence on the activity and safety of trastuzumab-containing neoadjuvant chemotherapy for the management of women with localised, irresectable or resectable breast cancer. Twenty-three published studies enrolling a total of 585 patients reported pathologic complete responses (pCR) ranging from 7 to 78% with a favourable adverse event profile, data that are presented and discussed in this review. The impact of trastuzumab on long-term outcome, the identification of surrogate biomarkers for sensitivity or resistance to antineoplastic therapy, the optimal schedule of trastuzumab administration and the more active chemotherapeutic regimen for synergism are only a few of the key points needing elucidation so as to rationalise trastuzumab-based approaches.
Περιγραφή
Λέξεις-κλειδιά
Antibodies, Monoclonal/*therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Agents/*therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Breast Neoplasms/chemistry/*drug therapy, Clinical Trials as Topic, Drug Synergism, Female, Humans, Neoadjuvant Therapy, Receptor, erbB-2/analysis
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/17766143
http://ac.els-cdn.com/S1040842807001576/1-s2.0-S1040842807001576-main.pdf?_tid=5a63ecbd6f0bc3a8a7cd2749281bd4da&acdnat=1333954257_8b29b9c8fb8c15ebe76a65cb676411cb
http://ac.els-cdn.com/S1040842807001576/1-s2.0-S1040842807001576-main.pdf?_tid=5a63ecbd6f0bc3a8a7cd2749281bd4da&acdnat=1333954257_8b29b9c8fb8c15ebe76a65cb676411cb
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής